Literature summary for 3.4.14.5 extracted from

Crepaldi, G.; Carruba, M.; Comaschi, M.; Del Prato, S.; Frajese, G.; Paolisso, G.
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes anagement (2007), J. Endocrinol. Invest., 30, 610-614.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	the oral dipeptidyl peptidase 4 inhibitors vildagliptin, sitagliptin, and saxagliptin are efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose. They have substantial advantages with respect to other anti-diabetic drugs, since they involve a low risk of hypoglycemia and do not affect body weight	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
saxagliptin	the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight	Homo sapiens
sitagliptin	the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight	Homo sapiens
vildagliptin	the oral dipeptidyl peptidase 4 inhibitor is efficious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose, the inhibitor has low risk of hypoglycemia and does not affect body weight	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
glucagon-like peptide-1 + H2O	-	Homo sapiens	?	-	?
glucose-dependent insulinotropic polypeptide + H2O	-	Homo sapiens	?	-	?

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)